Global Finance News
06 May 2026, 16:00
CVS Health Jumps 6% After Raising Full-Year Guidance on Insurance Margin Recovery
May 6, 2026 · Earnings Report
CVS Health surged 6% today after reporting first quarter 2026 results that beat expectations and prompted the company to raise its full-year earnings and cash flow guidance, with the Health Care Benefits segment delivering a dramatic improvement that reassured investors who had been watching the insurer's margin recovery closely.
Total revenues for the quarter came in at $100.4 billion, up 6.2% year-over-year, with growth across all three operating segments. GAAP diluted EPS rose to $2.30 from $1.41 in the prior year, while adjusted EPS increased to $2.57 from $2.25, beating expectations. Operating income jumped 38.7% to $4.68 billion, and adjusted operating income grew 12.5% to $5.15 billion. Cash flow from operations was $4.2 billion for the quarter.
The standout was the Health Care Benefits segment, which houses the Aetna insurance business. Adjusted operating income for the segment surged 52.6% to $3.04 billion, as the medical benefit ratio improved sharply to 84.6% from 87.3% a year ago, reflecting better underlying performance in the government business and the absence of a $448 million premium deficiency reserve recorded in the prior year. The improvement validated the company's much-discussed margin recovery plan, which had been a central concern for investors after a difficult 2025. Medical membership stood at 26.0 million as of March 31, down from 27.1 million a year ago, reflecting CVS's exit from the individual exchange business in 2026.
The Health Services segment, which includes pharmacy benefit management, posted revenues up 11.0% to $48.2 billion, though adjusted operating income dipped 7.1% to $1.49 billion due to continued pharmacy client price improvements. The Pharmacy and Consumer Wellness segment, which includes retail pharmacies, saw revenues hold roughly flat at $32.0 billion, with prescription volumes up 3.6% partly aided by the Rite Aid asset acquisitions completed in mid-2025, though adjusted operating income declined 8.8% due to reimbursement pressure and weather-related disruptions.
On the strategic front, CVS announced the launch of Health100, a health technology subsidiary that will use Google Cloud's AI technologies to deliver an integrated health care engagement platform for consumers. The company also unveiled plans for smaller pharmacy-focused retail locations and highlighted meaningful progress on prior authorization reform through Aetna, including approving more than 95% of eligible prior authorizations within 24 hours and eliminating over one million provider calls through automation.
For the full year 2026, CVS raised its GAAP diluted EPS guidance to a range of $6.24 to $6.44, up from the prior range of $5.94 to $6.14. Adjusted EPS guidance was lifted to $7.30 to $7.50 from $7.00 to $7.20, and cash flow from operations guidance was raised to at least $9.5 billion from at least $9.0 billion. The company noted it was maintaining a cautious view for the remainder of the year given continued elevated cost trends and potential macro headwinds.
May 6, 2026 · Earnings Report
CVS Health surged 6% today after reporting first quarter 2026 results that beat expectations and prompted the company to raise its full-year earnings and cash flow guidance, with the Health Care Benefits segment delivering a dramatic improvement that reassured investors who had been watching the insurer's margin recovery closely.
Total revenues for the quarter came in at $100.4 billion, up 6.2% year-over-year, with growth across all three operating segments. GAAP diluted EPS rose to $2.30 from $1.41 in the prior year, while adjusted EPS increased to $2.57 from $2.25, beating expectations. Operating income jumped 38.7% to $4.68 billion, and adjusted operating income grew 12.5% to $5.15 billion. Cash flow from operations was $4.2 billion for the quarter.
The standout was the Health Care Benefits segment, which houses the Aetna insurance business. Adjusted operating income for the segment surged 52.6% to $3.04 billion, as the medical benefit ratio improved sharply to 84.6% from 87.3% a year ago, reflecting better underlying performance in the government business and the absence of a $448 million premium deficiency reserve recorded in the prior year. The improvement validated the company's much-discussed margin recovery plan, which had been a central concern for investors after a difficult 2025. Medical membership stood at 26.0 million as of March 31, down from 27.1 million a year ago, reflecting CVS's exit from the individual exchange business in 2026.
The Health Services segment, which includes pharmacy benefit management, posted revenues up 11.0% to $48.2 billion, though adjusted operating income dipped 7.1% to $1.49 billion due to continued pharmacy client price improvements. The Pharmacy and Consumer Wellness segment, which includes retail pharmacies, saw revenues hold roughly flat at $32.0 billion, with prescription volumes up 3.6% partly aided by the Rite Aid asset acquisitions completed in mid-2025, though adjusted operating income declined 8.8% due to reimbursement pressure and weather-related disruptions.
On the strategic front, CVS announced the launch of Health100, a health technology subsidiary that will use Google Cloud's AI technologies to deliver an integrated health care engagement platform for consumers. The company also unveiled plans for smaller pharmacy-focused retail locations and highlighted meaningful progress on prior authorization reform through Aetna, including approving more than 95% of eligible prior authorizations within 24 hours and eliminating over one million provider calls through automation.
For the full year 2026, CVS raised its GAAP diluted EPS guidance to a range of $6.24 to $6.44, up from the prior range of $5.94 to $6.14. Adjusted EPS guidance was lifted to $7.30 to $7.50 from $7.00 to $7.20, and cash flow from operations guidance was raised to at least $9.5 billion from at least $9.0 billion. The company noted it was maintaining a cautious view for the remainder of the year given continued elevated cost trends and potential macro headwinds.